Contains the foot-and-mouth disease virus (FMDV) of Type O viruses synthetic peptide 2600,2700 and 2800 not less than 25μg/ml, respectively.

Contains the foot-and-mouth disease virus (FMDV) of Type O viruses peptide 2600,2700 less than 25μg/ml,respectively. Contains FMDV of Type A not less than 25μg/ml

Contains the inactivated foot-and-mouth disease virus (FMDV) Strain Re-O/MYA98/JSCZ/2013 and Strain Re‒A/WH/09. Each dose of the vaccine should contain a total 146S content of Type O and Type A viruses no less than 3.0μg, and the content of each virus type should not be less than 1.5μg.

The vaccine contains Porcine Circovirus Type 2 Cap recombinant protein from insect cells infected by recombinant baculovirus OKM strain, with antigen content no less than 16.0μg/ml.

The vaccine contains inactivated AV41 strains of Goatpox virus. The virus titer before inactivation is 106.2TCID50 per milliliter.

The vaccine contains two components (inactivated foot-and-mouth disease virus O/MYA98/BY/2010 strains and A/Re-A/WH/09 strains). The total antigen (146S) included type O and type A should not be less than 1.0μg/ml. The titer of O type virus is not less than 107.5 LD50 in 0.2ml (or not less than 10 7. 5 TCID50 in 1ml) and the titer of A type virus is not less than 107.0 LD50 in 0.2ml (or not less than 10 7. 5 TCID50 in 1ml).